Enterics

肠溶药

基本信息

批准号：
7678796
负责人：
RICHARD L GUERRANT
金额：
$ 37.09万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-03-01 至 2009-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7678796
关键词：
Animals Attenuated Bioterrorism Candidate Disease Gene Categories Characteristics Chlorine Clinical Colony-forming units Cryptosporidium Cryptosporidium parvum Detection Diagnostic Diagnostic Procedure Disease Disease Outbreaks Disinfection Doctor of Philosophy Dose Emerging Communicable Diseases Enteral Epidemic Escherichia Escherichia coli EHEC Escherichia coli Vaccines Food Gastroenteritis Genetic Determinism Genetic Predisposition to Disease Genome Genomics Goals Health Health Sciences Human Immunity Individual Ingestion Institutes Institution International Investigation Length Life Maryland Microarray Analysis Morbidity - disease rate Oocysts Oregon Organism Pathogenesis Predisposition Principal Investigator Production Propionibacterium acnes Publishing Religion and Spirituality Research Personnel Research Project Grants Resistance Restaurants Risk Role Route Salmonella Sampling Services Shigella Shigella dysenteriae Smallpox Supportive care Therapeutic Therapeutic Corynebacterium Parvum Therapeutic Intervention Time United States Universities Virginia Water Water Pollution Work antimicrobial biodefense commune enteric pathogen experience member mortality mucosal vaccine novel novel therapeutics novel vaccines oral vaccine pathogen programs respiratory tissue culture transmission process vaccine development vaccinology

项目摘要

Low Infectious Dose Entropathogens: Detection, Pathogenesis and Vaccinology Research Project V includes three Sub-Projects focused on key new aspects of the genomics, pathogenesis and vaccinology of the three leading Category B low-dose enteropathogens, and on their detection in clinical and environmental samples. These include the highly chlorine-resistant Cryptosporidium parvum, the most fearsome Shigella threat (S. dysenteriae 1) and the largely untreatable, Shiga toxinproducing enterohemorrhagic E. coil These three pathogens all pose serious risks as low infectious dose agents of bioterrorism as well as major national and global health endemic and epidemic challenges. The team of investigators for this project has a very strong track record of working with these organisms. Led by experienced investigators with international reputations in enteric diseases, Richard L. Guerrant and James B. Kaper, this project builds upon highly productive expertise and upon longstanding and new crossinstitutional synergies at UVa, UMd, VCU, VT, USUHS, UVt, and JHU. Our first Sub-Project V.1, on "Cryptosporidium genomics, pathogenesis and vaccinology" builds upon the near complete sequencing of the human (type 1) C. parvum genome by the VCU group, the published tissue culture, animal and field experience with Cryptosporidium by the UVa group, the plantbased production of mucosal vaccines at VT and on studies of the genetics of susceptibility at UVa, UVt, and JHU to identify and express type 1 (human) C. parvum candidate genes, define their roles in pathogenesis and immunity, express promising candidates and define genetic determinants of human susceptibility and thus optimal approaches to vaccine development. Sub-Project V.2 will engage UMd, USUHS and UVa colleagues to construct novel Shigella dysenteriae and enterohemorrhagic E. coli (EHEC) vaccines and develop novel therapeutics for EHEC disease. Sub-Project V.3 will produce additional diagnostic "deliverables" for detection of human fecal contamination of water (and possibly food) as well as the specific detection of the three low infectious dose category B enteropathogens on which our RCE Enterics Program is focused, C. parvum, S. dysenteriae and EHEC.

低传染剂量ro骨病：检测，发病机理和疫苗学研究项目V包括三个关注基因组学关键新方面的子项目： B低剂量肠病毒的三个领先类别的发病机理和疫苗学及其在临床和环境样品中检测。这些包括高度耐氯的隐孢子虫 Parvum，最可怕的志贺氏菌威胁（S. dysenteriae 1）和在很大程度上无法治疗的志贺毒品生产 Enterohemorrhagic E.这三种病原体都带来了严重的风险，因为生物恐怖主义的代理人以及主要的国家和全球健康流行和流行病挑战。这该项目的调查人员团队在与这些生物的合作方面有着非常有力的记录。领导经验丰富的调查员在肠道疾病方面拥有国际声誉，Richard L. Guerrant和James B. Kaper，该项目建立在高产专业知识和长期和新的跨机构的基础上 UVA，UMD，VCU，VT，USUHS，UVT和JHU的协同作用。我们的第一个子项目v.1在“隐孢子虫基因组学，发病机理和疫苗学”上建立在对人（1型）C。parvum基因组的几乎完整的测序后，VCU组， UVA组的隐孢子虫（Cryptosporidium）发表的组织培养，动物和田间经验，基于植物在VT和对UVA UVA易感性遗传学的研究中生产粘膜疫苗和jhu识别并表达1型（人）C。parvum候选基因，定义它们在发病机理和免疫力，表达有希望的候选者并定义人类的遗传决定因素易感性，因此是疫苗开发的最佳方法。子项目v.2将参与UMD， USUHS和UVA同事构建新颖的Shigella dysenteriae和Enterohemorrhagic E. Coli（EHEC）疫苗并为EHEC疾病开发新的治疗剂。子项目v.3将产生额外诊断“可交付成果”，用于检测人类粪便的水（以及可能的食物）以及我们RCE的三种低传染剂量类别B肠病毒的特定检测 Enterics计划的重点是C. Parvum，S。Dysenteriae和EHEC。